Orexo ABORXOF 34 Cyclically Adjusted PB Ratio is 1.84 as of Jun. 24, 2026, which is 26% below its 10-year median of 2.50. GuruFocus rates ORXOF with a GF Score™ of 34/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 758 Drug Manufacturers companies, Orexo AB ranks worse than 52.24% on this metric.
The historical rank and industry rank for Orexo AB's Cyclically Adjusted PB Ratio or its related term are showing as below:
ORXOF'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.69 Med: 2.5 Max: 6.84
Current: 1.93
During the past years, Orexo AB's highest Cyclically Adjusted PB Ratio was 6.84. The lowest was 0.69. And the median was 2.50.
ORXOF's Cyclically Adjusted PB Ratio is ranked worse than 52.24% of 758
companies
in the Drug Manufacturers industry
Industry Median: 1.81
vs ORXOF: 1.93
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Orexo AB's adjusted book value per share data for the three months ended in Mar. 2026 was $1.114. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.14 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Orexo AB (OTCPK:ORXOF) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Orexo AB Cyclically Adjusted PB Ratio Related Terms
Orexo AB Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Orexo AB's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ORXOF vs ZTS: Cyclically Adjusted PB Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orexo AB Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Orexo AB's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Orexo AB's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 1.84 mean?
Orexo AB (ORXOF) has a Cyclically Adjusted PB Ratio of 1.84 as of Jun. 24, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Orexo AB and its competitors. This is 26% below median its historical median of 2.50. Over the past decade, Orexo AB's Cyclically Adjusted PB Ratio has ranged from 0.69 to 6.84. According to the industry distribution chart, Orexo AB ranks #396 out of 758 companies in the Drug Manufacturers industry, placing it in the top 52.2%.
Is Orexo AB's Cyclically Adjusted PB Ratio too high?
Orexo AB's current Cyclically Adjusted PB Ratio of 1.84 is 26% below median its 10-year median of 2.50. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 6.84. The Drug Manufacturers industry median Cyclically Adjusted PB Ratio is 1.81. Orexo AB's value of 1.84 is 1.7% above this industry median. Based on the distribution chart, Orexo AB ranks #396 out of 758 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Orexo AB has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Cyclically Adjusted PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orexo AB ranks #396 out of 758 companies for Cyclically Adjusted PB Ratio. This places Orexo AB in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 1.81. Orexo AB's value of 1.84 is 1.7% above this benchmark. Historically, Orexo AB's own Cyclically Adjusted PB Ratio has ranged from 0.69 to 6.84 over the past decade. While the company's 10-year median is 2.50 vs. the industry median of 1.81, Orexo AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Drug Manufacturers company?
The median Cyclically Adjusted PB Ratio among Drug Manufacturers companies is 1.81, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orexo AB's current Cyclically Adjusted PB Ratio of 1.84 is 1.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Orexo AB and its competitors. For the Drug Manufacturers industry, the median Cyclically Adjusted PB Ratio is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orexo AB's current Cyclically Adjusted PB Ratio is 1.84, which is 26% below median its own 10-year median of 2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (ORXOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.10 — trading 208.8% above its estimated fair value. The current Cyclically Adjusted PB Ratio is 1.84, which is 26% below median its 10-year median of 2.50 and 1.7% above the Drug Manufacturers industry median of 1.81. Orexo AB's overall GF Score™ is 34/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Orexo AB (ORXOF), the current Cyclically Adjusted PB Ratio is 1.84 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orexo AB (ORXOF) Overvalued in 2026?
Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued.
The current stock price of $2.10 is trading 208.8% above its estimated GF Value™ of $0.68.
GuruFocus considers Orexo AB to be Significantly Overvalued.
Key valuation signals for ORXOF:
Cyclically Adjusted PB Ratio: 1.84 (26% below median its 10-year median of 2.50)
GF Value™: $0.68 vs. price of $2.10 (208.8% above fair value)
Industry Position: 1.7% above the Drug Manufacturers median (#396 of 758)
No single metric tells the full story. See the ORXOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
34GF Score
Get the complete analysis for ORXOF
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ORXOF has been successfully added to your 
